

QUARTERLY REPORT

01ST OF JANUARY TO 31ST OF MARCH 2018

Letter to Our Stockholders

Dear Stockholders:

The NEXUS team also had extremely positive results in the first quarter of the current year. We are proud that both sales and earnings increased significantly again.

The increase in sales amounted to approx. 11 % in the first quarter compared with the previous year. The result before taxes and interest (EBIT) also increased by approx. 13 %. Operating cash flow reached EUR 17.3 million and consequently was nearly to the very strong previous year. The good business figures are due in particular to our new product generation "NEXUS / NEXT GENERATION" and our stable license business.

NEXUS / NEXT GENERATION (NG) is being very well received by our customers, which is clearly shown in increasing incoming orders and sales figures. Our customers evaluate it as very positive that we not only present a further technical development with NG, but also that the implementation of completely intuitive prompting is in the foreground. We have taken a new and courageous path with this and have designed our software as completely process-oriented and user-related. This has proven to be worth the effort, and we expect further increasing demand for our products.

Another important product topic of the first quarter concerned our mobile apps. In this area, there is also an increasing demand from hospitals for mobility in the use of their NEXUS systems.


Highlights Q1 2018 - Company development

- + Strong increases in sales in the 1st quarter
- + Increasing demand for NEXUS / HIS^{NG}
- + Market entry in Poland
- + Necessary reorganizations in two business areas

Both domestically and abroad we have been able to win a variety of new and interesting projects. Outstanding is certainly the decision of the French ELSAN group, with a total of 52 hospitals, to switch to our new HIS version Emed5. On the project side, we have been able to reach further milestones with major orders from Deutsche Rentenversicherung (German Old-Age Pension Insurance) and Hirslanden Hospital. In the Netherlands, we have implemented use of


Development of Group Sales (3 months) in KEUR

2007-2018



Development of Group Earnings before Interest and Taxes (3 months) KEUR

2007-2018



the first fully integrated medication solution. This is an important step to win market shares in the Netherlands with the new software generation. In our innovation project "ENDOBASE NEXT", which we implement together with Olympus, we were able to meet a series of milestones on the product side in the first quarter and support the sales process.

In addition to these pleasing developments, we also have to deal with organizational challenges that resulted in project and service problems. We have implemented organizational adjustments to increase customer satisfaction in two areas. We must continue to work intensively in the coming months on this to fulfill our high standards of customer orientation.

Very positive is our acquisition in Poland, which we also concluded in the first quarter. The company - now under the name NEXUS Polska - fits very well to NEXUS strategically with approx. 90 employees and a solid customer base in the HIS business. As in previous cases, we will modernize and supplement the company's existing software with our NEXT / NEXUS product line. The goal is to improve our market position significantly in Poland based on the new and expanded product base. The first quarter started in a very promising way with many new customers.

Dear Shareholders, you see that we are also consistently pursuing our long-term goals in addition to healthy growth. The core topics "European expansion" and "NEXT / NEXUS" are at the top of our priority list. Its success will depend on whether we can achieve our long-term goal of becoming the European market leader.

We want to thank you, dear Shareholders, for your trust.

Warm regards,

Dr. Ingo Behrendt
CEO



Financial Highlights

1ST QUARTER 2018 AND 2017

| | 31/03/2018 | 31/03/2017 | Changes |
|--|-------------|-----------------------|-------------|
| | KEUR | KEUR | (in %) |
| Sales | 32,044 | 28,940 | 10.7 |
| Healthcare Software Sales | 29,511 | 25,932 | 13.8 |
| Healthcare Service Sales | 2,533 | 3,008 | -15.8 |
| Domestic sales | 16,661 | 14,276 | 16.7 |
| Sales in foreign countries | 15,383 | 14,664 | 4.9 |
| Earnings before tax on income (EBT) | 3,253 | 2,940 | 10.6 |
| Earnings before interest and taxes (EBIT) | 3,293 | 2,926 | 12.5 |
| EBITA | 4,021 | 3,520 | 14.2 |
| EBITDA | 5,792 | 5,411 | 7.0 |
| Consolidated surplus | 2,511 | 2,503 | 0.3 |
| Cash flow from current business transactions | 17,285 | 18,153 | -4.8 |
| Net income per share (undiluted/diluted) in EUR | 0.17 / 0.17 | 0.15 / 0.15 | 13.3 / 13.3 |
| Share price (closing price, XETRA) in EUR | 25.10 | 20.21 | 24.2 |
| Capitalization of software developments | 1,171 | 1,289 | -9.2 |
| Depreciation | 2,499 | 2,485 | 0.6 |
| Acquisition-related depreciations from purchase price allocation | 728 | 594 | 22.6 |
| Fixed Assets (without deferred taxes) | 101,542 | 94,781 ¹⁾ | 7.1 |
| Current Assets / Short-Term Assets | 72,920 | 68,571 | 6.3 |
| Net Liquidity | 38,559 | 34,111 | 13.0 |
| Equity Capital | 104,480 | 103,009 ¹⁾ | 1.4 |
| Employees | 1,077 | 918 | 17.3 |

1) out-off date 31 December 2017

Interim Annual Report

REPORT ABOUT PROFIT, FINANCIAL AND ASSET SITUATION

NEXUS Group sales increased from KEUR 28,940 to KEUR 32,044 (+10.7 %) in the first three months of the year 2018.

The sustained steady sales development of NEXUS Group of recent years could be continued. The Healthcare Software Division developed very positively (+13.8 %) and achieved sales of KEUR 29,511 following KEUR 25,932 (3M-2017) in the previous year. Sales of KEUR 2,533 were achieved in the Healthcare Service Division following KEUR 3,008 (3M-2017) (-15.8 %). Project delays have occurred in this division, which have been reflected in sales.

We were able to increase sales in Germany by 16.7 % to KEUR 16,661 (3M-2017: KEUR 14,276). In international business, we recorded sales of KEUR 15,383 in the first quarter 2018 compared to KEUR 14,664 in the previous year (+4.9 %). The weaker exchange rate of the Swiss Franc resulted in a reduction in sales of KEUR 336 and an impact on earnings of KEUR 86. The average exchange rate of the Swiss franc of SFR 1.17 on 31 March 2018 was above the average price on 31 December 2017 (SFR 1.11).

However, the Group result before interest and taxes (EBIT) increased considerably anyway. It improved by 12.5 % to KEUR 3,293 (3M-2017: KEUR 2,926). A value of KEUR 4,021 was achieved in EBITA and consequently was 14.2 % above the value of previous year (3M-2017: KEUR 3,520). EBITDA reached KEUR 5,792 in the first quarter of 2018 (3M-2017: KEUR 5,411) and consequently was 7.0 % higher than in the previous year.

The cash flow from on-going business transactions continued to develop positively. We achieved a value of KEUR 17,285 (3M-2017: KEUR 18,152) there. The main reason for the strong cash flow in the first quarter is the high incoming payments from the maintenance revenues.

The consolidated surplus amounted to KEUR 2,511 for the first quarter 2018 following KEUR 2,503 (3M-2017). The undiluted earnings per share reached 17 cents (previous year: 15 cents) (diluted: 17 cents; previous year: 15 cents).


Cash resources including short-term financial assets amounted to KEUR 38,559 on 31 March 2018 (31 March 2017: KEUR 34,111). Investments in tangible and intangible assets were made in the amount of KEUR 2,085 in the

first quarter 2018 (3M-2017: KEUR 2,794). This includes KEUR 1,171 (3M-2017: KEUR 1,289) for capitalizing software developments. For the acquisition of consolidated companies were total KEUR 3,828 invested.

The balance sheet total increased from KEUR 151,279 to KEUR 175,980 compared to 31 December 2017. Intangible assets, goodwill and balanced-out deferred taxes add up to a total of KEUR 85,755 following KEUR 81,051 (31 December 2017). Receivables from customers amount to KEUR 26,692 following KEUR 21,686 on 31 December 2017.


EBITDA (3 MONTHS) IN KEUR

+7.0 % compared to previous year



CASH FLOW FROM CURRENT BUSINESS TRANSACTIONS (3 MONTHS) IN KEUR

-4.8 % compared to previous year



Employees

NEXUS Group employed a total of 1,077 people as of 31 March 2018 (31 March 2017: 918 employees).

Effect of applying IFRS 15 as of 01 January 2018

At the date of conversion on 01 January 2018, NEXUS Group applied the modified retrospective method to contracts not yet completed. From the conversion within the context of IFRS 15, the revenue reserve of the NEXUS Group increased by approx. KEUR 202. IFRS 15 compared to IAS 18 does not result in significant conversion effects for the first quarter of 2018.

Acquisition of MedHub sp. z o.o., Poznan (Polen)

NEXUS AG acquired 55.0 % of the shares of MedHub sp. z o.o., Poznan (Poland), on 09 January 2018. With more than 90 employees and more than 120 hospital customers, the company is one of the top three providers of medical software in Poland. MedHub is a recognized leader in electronic patient records, including pharmaceutical and laboratory solutions. In the future, the company will operate as NEXUS Polska on the market.

Further information can be found in the Annual Report 2017, Page 93.

Finance Highlights Q1 2018

- + 10.7 % sales increase in 1st quarter 2018 from KEUR 28,940 (3M-2017) to KEUR 32,044
- + 12.5 % increase in the Group result for earnings before interest and taxes (EBIT) from KEUR 2,926 (3M-2017) to KEUR 3,293
- + Continued very strong operational cash flow in the 1st quarter of KEUR 17,285
- + High net liquidity of KEUR 38,559

Events after the Balance Sheet Date

There were no events requiring reporting after the balance sheet key date.

Annual Stockholders Meeting and Dividends

At the Annual Stockholders Meeting of NEXUS AG in Donaueschingen on 27 April 2018, the Executive Board and Supervisory Board proposed to pay a one cent higher dividend of EUR 0.16 to shareholders than the previous year from the retained earnings of fiscal year 2017. The proposal was adopted by the required majority. Consequently, there was a total distribution of KEUR 2,519 on 03 May 2018.

SALES BY REGION

| | 01/01/-31/03/2018 | 01/01/-31/03/2017 | Changes |
|-----------------|-------------------|-------------------|-------------|
| | KEUR | KEUR | % |
| Germany | 16,661 | 14,276 | 16.7 |
| Switzerland | 7,821 | 8,380 | -6.7 |
| Netherlands | 3,310 | 3,644 | -9.2 |
| France | 1,436 | 1,344 | 6.8 |
| Austria | 745 | 661 | 12.7 |
| Other countries | 2,071 | 635 | 226.1 |
| TOTAL | 32,044 | 28,940 | 10.7 |

SALES BY DIVISION

| | 01/01/-31/03/2018 | 01/01/-31/03/2017 | Changes |
|---------------------|-------------------|-------------------|-------------|
| | KEUR | KEUR | % |
| Healthcare Software | 29,511 | 25,932 | 13.8 |
| Healthcare Service | 2,533 | 3,008 | -15.8 |
| TOTAL | 32,044 | 28,940 | 10.7 |

Capital market, event and finance data

INVESTOR RELATIONS

Active communication with our stockholders, potential investors, analysts and the finance market are the focal point of our investor relation activities. We continually inform all market participants promptly and comprehensively via press releases and ad hoc announcements as well as the mandatory quarterly, semi-annual and annual financial reports.

In addition, we cultivate intensive dialog with institutional investors and finance analysts via one-on-one meetings and on roadshows. Our Investor Relations team is of course at your disposal as contact persons.

08. May 2018

Quarterly Report Q1 / 2018

14. August 2018

Semi-Annual Report 2018

06. November 2018

Quarterly Report Q3 / 2018

26. - 28. November 2018

Analyst Event, Frankfurt

Frankfurt Stock Exchange stock prices (1-year period)



Stock Market Highlights (XETRA closing prices)

- + Initial listing on 02 January 2018: 26.30 €
- + Highest price on 16 January 2018: 30.20 €
- + Stock market capitalization on 29 March 2018: 395.4 million €

09. May - 12. May 2018

Deutscher Röntgenkongress, Leipzig

10. May - 12. May 2018

Healthio, Barcelona

15. May - 17. May 2018

Pflege Plus, Stuttgart

24. May - 26. May 2018

Jahrestagung Deutsche Gesellschaft für Pathologie, Berlin

27. May - 29. May 2018

HIMSS Europe, Barcelona

29. May - 31. May 2018

HIT, Paris

08. June - 09. June 2018

Kongress der Deutschen Gesellschaft für Pränatal- und Geburtsmedizin, Berlin

15. June - 16. June 2018

HISTOLOGICA, Oberhausen

01. July - 04. July 2018

ESHRE, Barcelona

NEXUS Group Information and Outlook

Chances and Risks Report

Please refer to the explanations in the annual report of 31 December 2017 for information about the essential chances and risks in the development of NEXUS Group. There have been no essential changes in the meantime.

Directors' Holdings

The director's holders of the Supervisory Board and the Executive Board are as follows on 31 March 2018 in comparison to the previous year: cf. Table.

| Supervisory Board | Numbers of stock owned | Numbers of options |
|------------------------------------|------------------------------------|------------------------|
| Dr. jur. Hans-Joachim König | 69,900 Previous year (89,900) | 0 Previous year (0) |
| Prof. Dr. Alexander Pocsay | 121,500 Previous year (121,500) | 0 Previous year (0) |
| Prof. Dr. Ulrich Krystek | 0 Previous year (0) | 0 Previous year (0) |
| Wolfgang Dörflinger | 0 Previous year (0) | 0 Previous year (0) |
| Gerald Glasauer | 0 Previous year (0) | 0 Previous year (0) |
| Prof. Dr. med Felicia M. Rosenthal | 520 Previous year (315) | 0 Previous year (0) |

| Executive Board | Numbers of stock owned | Numbers of options |
|-------------------|------------------------------------|------------------------|
| Dr. Ingo Behrendt | 111,900 Previous year (111,900) | 0 Previous year (0) |
| Ralf Heilig | 127,650 Previous year (137,650) | 0 Previous year (0) |
| Edgar Kuner | 240,351 Previous year (250,351) | 0 Previous year (0) |

Outlook: Address urgent challenges

The first quarter 2018 was again very positive. A sales increase of approx. 11 % and an increase in earnings before interest and taxes (EBIT) of approx. 13 % as well as a high operating cash flow of approx. € 17 million represent a great start into the current year. We were able to continue the positive development of the past years unabated. We are on the right course for the future with our strategic projects NEXT / NEXUS, Olympus "ENDOBASE NEXT" and European expansion.

However, we note at the same time that our company is faced with new challenges as it has become larger. We are not organized in parts in such a way that we can provide the expected customer performance. Especially in the service sector, we have a need for catching up, a need which we already addressed in the first quarter. The topic will keep us busy in the current year and will also lead to partially higher costs.

Thanks to our highly differentiated and innovative product portfolio and a good European presence, we have a very attractive position on the market. However, the way to become the European market leader can only succeed if we constantly increase our performance and adapt our work organization in addition to growth. We have succeeded in pursuing these challenging projects parallel up to now. The NEXUS team continues to look forward to these challenges.

Accounting and Valuation Methods

This interim report from the NEXUS Group of 31 March 2018 has been prepared in keeping with the International Financial Reporting Standards (IFRS) as they are applied in the EU. The interpretations of the International Financial Reporting Interpretation Committee (IFRIC) have been taken into account.

The regulations of IAS 34 were observed in the interim report of 31 March 2018. This refers to a summarized report, which does not contain all information of an IFRS Group Financial Statement, and consequently this report should be read in connection with the Appendix of the Group Financial Statement 2017. The same accounting and valuation methods were used in the Group Financial Statement for the business year 2017. The report has not been audited.



„Time is a precious commodity in medical care. We provide you with a little bit more of it.“

NEXUS – MEDICINE IN FOCUS

Group profit and loss account

**FOR THE PERIOD FROM
01 JANUARY TO 31 MARCH 2018 AND 2017**

| | 01/01/-31/03/2018 | 01/01/-31/03/2017 |
|--|-------------------|-------------------|
| | KEUR | KEUR |
| Revenue | 32,044 | 28,940 |
| Development work capitalized | 1,171 | 1,289 |
| Other operating income | 661 | 690 |
| Cost of materials including purchased services | 5,824 | 5,051 |
| Personnel costs | 18,609 | 17,108 |
| Depreciation | 2,499 | 2,485 |
| Other operating expenses | 3,651 | 3,349 |
| OPERATING RESULT | 3,293 | 2,926 |
| Finance Income | 35 | 58 |
| Finance Expenses | 75 | 44 |
| RESULT BEFORE TAX ON PROFIT | 3,253 | 2,940 |
| Taxes on profit | 742 | 437 |
| CONSOLIDATED SURPLUS | 2,511 | 2,503 |
| Of the consolidated surplus, accounted to: | | |
| - Stockholders of NEXUS AG | 2,601 | 2,306 |
| - Shares of non-controlling partners | -90 | 197 |
| CONSOLIDATED NET EARNINGS PER SHARE IN EUR | | |
| Weighted average (undiluted/diluted) of issued shares in circulation (in thousands) | 15,724 / 15,724 | 15,733 / 15,784 |
| Undiluted / diluted | 0.17 / 0.17 | 0.15 / 0.15 |

Group Statement of Consolidated Income

**FOR THE PERIOD FROM
01 JANUARY TO 31 MARCH 2018 AND 2017**

| | 01/01/-31/03/2018 | 01/01/-31/03/2017 |
|--|-------------------|-------------------|
| | KEUR | KEUR |
| Consolidated surplus | 2,511 | 2,503 |
| Actuarial profits and losses | 0 | 25 |
| Tax effects | 0 | -22 |
| Currency conversion differences | -674 | -3 |
| OTHER OVERALL RESULT | -674 | 0 |
| OVERALL RESULT OF THE PERIOD | 1,837 | 2,503 |
| Of the overall result of the period, accounted to: | | |
| - Stockholders of NEXUS AG | 1,931 | 2,304 |
| - Shares of non-controlling partners | -94 | 199 |

Consolidated Balance Sheet

AS OF 31 MARCH 2018 AND 31 DECEMBER 2017

| ASSETS | 31/03/2018 | 31/12/2017 |
|---|----------------|----------------|
| | KEUR | KEUR |
| LONG-TERM ASSETS | | |
| Goodwill | 53,499 | 49,314 |
| Other intangible assets | 36,885 | 35,804 |
| Fixed (Intangible) assets | 10,139 | 9,407 |
| Shares in companies valued at equity | 31 | 31 |
| Deferred tax assets | 2,058 | 2,169 |
| Other financial assets | 448 | 225 |
| Total of Long-Term Assets | 103,060 | 96,950 |
| SHORT-TERM ASSETS | | |
| Inventories | 604 | 574 |
| Trade receivables and other receivables | 26,692 | 21,686 |
| Receivables from tax on profits | 1,467 | 783 |
| Other non-financial assets | 4,928 | 2,196 |
| Other financial assets | 670 | 705 |
| Short-term financial assets | 1,785 | 1,849 |
| Cash and balance in bank | 36,774 | 26,536 |
| Total of Short-Term Assets | 72,920 | 54,329 |
| Balance Sheet Total | 175,980 | 151,279 |

| EQUITY AND LIABILITIES | 31/03/2018 | 31/12/2017 |
|--|----------------|----------------|
| | KEUR | KEUR |
| EQUITY CAPITAL | | |
| Subscribed capital | 15,752 | 15,752 |
| Capital reserves | 34,572 | 34,953 |
| Retained earnings | 58,034 | 48,202 |
| Consolidated surplus | 2,601 | 9,832 |
| Other cumulated Group result | -6,874 | -6,204 |
| Own shares | -404 | -419 |
| EQUITY CAPITAL ATTRIBUTABLE TO STOCKHOLDERS OF THE PARENT COMPANY | 103,681 | 102,116 |
| Shares of non-controlling partners | 799 | 893 |
| Total Equity Capital | 104,480 | 103,009 |
| LONG-TERM DEBTS | | |
| Pension obligations | 10,442 | 10,515 |
| Deferred tax liabilities | 6,687 | 6,236 |
| Other financial debts | 6,106 | 5,148 |
| Total of Long-Term Debts | 23,235 | 21,899 |
| SHORT-TERM DEBTS | | |
| Accruals | 1,258 | 2,240 |
| Financial liabilities | 4,136 | 5,607 |
| Liabilities from tax on profit | 1,503 | 1,126 |
| Deferred revenue | 22,794 | 2,391 |
| Other non-financial debts | 10,306 | 7,625 |
| Other financial debts | 8,268 | 7,382 |
| Total of Short-Term Debts | 48,265 | 26,371 |
| Balance Sheet Total | 175,980 | 151,279 |

Consolidated Cash Flow Statement

**FOR THE PERIOD FROM
01 JANUARY TO 31 MARCH 2018 AND 2017**

| | 2018 | 2017 |
|--|---------------|---------------|
| | KEUR | KEUR |
| 1. CASH FLOW FROM CURRENT BUSINESS TRANSACTIONS | | |
| Group annual result before tax on income | 3,253 | 2,940 |
| Write-offs (+) / write-ups (-) on intangible assets, tangible assets and financial assets | 2,499 | 2,485 |
| Other expenses not affecting payment (+) / revenue (-) | -1,797 | 910 |
| Increase (-) / decrease (+) in inventories | -30 | 332 |
| Gain (-) / loss (+) on disposal of fixed assets and securities | 30 | 95 |
| Increase (-) / decrease (+) in receivables and other assets from operating activities | -7,139 | -10,194 |
| Increase (+) / decrease (-) of accruals insofar as not entered in other comprehensive income | -982 | -60 |
| Increase (+) / decrease (-) in liabilities from operating activities | 22,051 | 22,256 |
| Paid interest (-) | -11 | -46 |
| Received interest (+) | 35 | 59 |
| Taxes on profit paid (-) | -624 | -628 |
| Taxes on profit received (+) | 0 | 3 |
| | 17,285 | 18,153 |
| 2. CASH FLOW FROM INVESTMENT ACTIVITIES | | |
| Payments (-) for investments in intangible and fixed assets | -2,085 | -2,794 |
| Payments (-) for the acquisition of companies consolidated minus cash acquired | -3,828 | 0 |
| Payments (-) / receipts (+) from the acquisition/disposal of short-term financial assets | 0 | -99 |
| | -5,913 | -2,893 |
| 3. CASH FLOW FROM FINANCING ACTIVITIES | | |
| Share issue (-) in the context of share-based compensation | -351 | 0 |
| Payments (-) for the acquisition of own shares | -15 | -50 |
| Receipts (+) from the sale of own shares | 0 | 21 |
| | -366 | -29 |
| Cash relevant changes in cash and cash equivalents (sum of 1 + 2 + 3) | 11,006 | 15,231 |
| Exchange rate changes on cash and cash equivalents | -768 | -35 |
| Cash and cash equivalents at beginning of period | 26,536 | 15,923 |
| Cash and cash equivalents at end of period | 36,774 | 31,119 |
| COMPOSITION OF CASH AND CASH EQUIVALENTS | | |
| Liquid funds | 36,774 | 31,119 |
| | 36,774 | 31,119 |

Group Statement of Changes in Equity

AS OF 31 MARCH 2018 AND 31 MARCH 2017

| | Subscribed capital | Capital reserves | Retained earnings | Annual Net Profit | Equity capital difference from currency conversion | Pension reserves | Own shares | Equity capital attributable to stock of parent company | Shares of non-controlling partners | Equity capital total | Authorized Capital |
|--|--------------------|------------------|-------------------|-------------------|--|------------------|------------|--|------------------------------------|----------------------|--------------------|
| | KEUR | KEUR | KEUR | KEUR | KEUR | KEUR | KEUR | KEUR | KEUR | KEUR | KEUR |
| CONSOLIDATED EQUITY AS OF 01/01/2017 | 15,736 | 34,307 | 42,414 | 8,146 | 2,827 | -7,582 | -224 | 95,604 | 198 | 95,802 | 3,000 |
| Posting of consolidated surplus 2016 in the Group profit carried forward | | | 8,146 | -8,146 | | | | 0 | | 0 | |
| Currency differences | | | 126 | | -81 | -47 | | -2 | 2 | 0 | |
| OTHER COMPREHENSIVE INCOME AFTER TAXES AS OF 31/03/2017 | 0 | 0 | 126 | 0 | -81 | -47 | 0 | -2 | 2 | 0 | 0 |
| Consolidated surplus 3M-2017 | | | | 2,306 | | | | 2,306 | 197 | 2,503 | |
| OVERALL RESULT OF THE PERIOD | 0 | 0 | 126 | 2,306 | -81 | -47 | 0 | 2,304 | 199 | 2,503 | 0 |
| Purchase of own shares | | -47 | | | | | -3 | -50 | | -50 | |
| Sale of own shares | | 20 | | | | | 1 | 21 | | 21 | |
| Stock-Based Payment | | 66 | | | | | | 66 | | 66 | |
| CONSOLIDATED EQUITY AS OF 31/03/2017 | 15,736 | 34,346 | 50,686 | 2,306 | 2,746 | -7,629 | -246 | 97,946 | 397 | 98,344 | 3,000 |
| CONSOLIDATED EQUITY AS OF 01/01/2018 | 15,752 | 34,953 | 48,202 | 9,832 | 889 | -7,093 | -419 | 102,116 | 893 | 103,009 | 2,984 |
| Posting of consolidated surplus 2017 in the Group profit carried forward | | | 9,832 | -9,832 | | | | 0 | | 0 | |
| Currency differences | | | | | -160 | -510 | | -670 | -4 | -674 | |
| OTHER COMPREHENSIVE INCOME AFTER TAXES AS OF 31/03/2018 | 0 | 0 | 0 | 0 | -160 | -510 | 0 | -670 | -4 | -674 | 0 |
| Consolidated surplus 3M-2018 | | | | 2,601 | | | | 2,601 | -90 | 2,511 | |
| OVERALL RESULT OF THE PERIOD | 0 | 0 | 0 | 2,601 | -160 | -510 | 0 | 1,931 | -94 | 1,837 | 0 |
| Purchase of own shares | | | | | | | -396 | -396 | | -396 | |
| Sale and issue of own shares in the form of share-based payment | | -381 | | | | | 411 | 30 | | 30 | |
| CONSOLIDATED EQUITY AS OF 31/03/2018 | 15,752 | 34,572 | 58,034 | 2,601 | 729 | -7,603 | -404 | 103,681 | 799 | 104,480 | 2,984 |

Declaration according to § 37y No. 1 WpHG

To the best of our knowledge, and in accordance with the applicable reporting principles for interim financial reporting, the interim consolidated financial statements give a true and fair view of the assets, liabilities, financial position and profit or loss of the group, and the interim management report of the group includes a fair review of the development and performance of the business and the position of the group, together with a description of the principal opportunities and risks associated with the expected development of the group for the remaining months of the financial year.

Donaueschingen, 08 May 2018

NEXUS AG
The Executive Board

nexus | ag

NEXUS AG, Irmastraße 1, D-78166 Donaueschingen
Phone +49 771 22960-0, Fax +49 771 22960-226
www.nexus-ag.de, info@nexus-ag.de